Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1266 participants.

Also called NCT07912970

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,266 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07912970
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07912970. Randomized; single masking; primary purpose treatment. Start 2027-04-01 (anticipated); primary completion 2029-12-01 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Tenecteplase Bridging Thrombolysis Prior to Inter-hospital Transfer for Endovascular Therapy in Anterior Circulation Large Vessel Occlusion Stroke Within 4.5-24 Hours
Acronym
Union-transfer
Condition
Acute Ischemic Stroke
Condition
Large Vessel Occlusion
Intervention (Drug)
Tenecteplase (rhTNK-tPA) (0.25 mg/kg, to maximum of 25mg)
Lead sponsor
Fujian Medical University Union Hospital (class: other)
Collaborator
Zhangzhou Affiliated Hospital of Fujian Medical University (class: other)

Record details

Record id
cardio:ct-nct07912970
Content hash
76db7395a73bdc2874cb43b2695687141dbdb5ff0f555eac981f2715eb49f8b3